医学临床研究
   Jul. 14, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2020, Vol. 37 Issue (7): 998-1001    DOI: 10.3969/j.issn.1671-7171.2020.07.012
Current Issue | Archive | Adv Search |
Effect of Simvastatin Combined with Thrombolytic Enzyme on Cerebral Thrombosis Patients
SI Li-li, ZHAO De-tao, HAN Xu
Department of neurology,Guangrao County People's Hospital Dongying Shandong 257300
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To explore the effect of simvastatin combined with thromboplastin on cerebral thrombosis patients and its influence on coagulation factor level. 【Methods】 A total of 108 cerebral thrombosis patients admitted to our hospital from July 2016 to July 2018 were selected. According to simple random method, patients were divided into the control group (n=54) and the research group (n=54),The control group was treated with Agkistrodon halys antithrombotic enzyme. The research group was treated with simvastatin in addition to the drug of the control group. The clinical efficacy, changes of carotid intima-media thickness (CIMT), plaque area, coagulation factor, coagulation time, blood lipid index, stroke scale of the National Institutes of Health (NIHSS) and the occurrence of adverse reactions in both groups were compared before and after treatment.【Results】 The total effective rate of the research group was higher than that of the control group (92.59% vs 68.52%, χ2=18.494; P<0.05). Before treatment, there was no significant difference in CIMT, plaque area, coagulation factor, coagulation time, blood lipid index between the two groups (P>0.05). After treatment, the CIMT, plaque area, coagulation factors, coagulation time, low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) of the two groups were all lower than those before treatment (P<0.05), except that the high density lipoprotein cholesterol (HDL-C) levels of the two groups were higher than before treatment (P<0.05). Of which, the above indicators of the research group were better than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Simvastatin combined with antithrombotic enzyme can improve the therapeutic effect of cerebral thrombosis, reduce the level of coagulation factors and improve blood lipid metabolism and neurological function without significantly increasing adverse reactions.
Key wordsIntracranial Thrombosis      Hydroxymethylglutaryl-CoA Reductase Inhibitors/TU     
Received: 01 July 2019     
PACS:  R743.32  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
SI Li-li
ZHAO De-tao
HAN Xu
Cite this article:   
SI Li-li,ZHAO De-tao,HAN Xu. Effect of Simvastatin Combined with Thrombolytic Enzyme on Cerebral Thrombosis Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(7): 998-1001.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.07.012     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I7/998
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech